Personalis, Inc.

How big is Personalis, Inc.?

As of Jun 18, Personalis, Inc. has a market capitalization of 550.27 million and reported net sales of 85.70 million with a net profit of -84.07 million over the latest four quarters. Shareholder's funds are 202.96 million, and total assets amount to 270.27 million.

As of Jun 18, Personalis, Inc. has a market capitalization of 550.27 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 85.70 million, while the sum of net profit for the same period is -84.07 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 202.96 million, and total assets amount to 270.27 million.

What does Personalis, Inc. do?

Personalis, Inc. is a cancer genomics company that provides molecular data to develop personalized cancer therapies. As of March 2025, it reported net sales of $21 million and a net loss of $16 million, with a market cap of $550.27 million.

Overview: <BR>Personalis, Inc. is a cancer genomics company focused on developing therapies by providing molecular data about each patient’s cancer and immune response, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 21 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 550.27 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.84 <BR>Return on Equity: -40.54% <BR>Price to Book: 2.65<BR><BR>Contact Details: <BR>Address: 1330 Obrien Dr, MENLO PARK CA: 94025-1436 <BR>Tel: 1 650 7521300 <BR>Fax: 1 302 5313150 <BR>Website: http://www.personalis.com/

Should I buy, sell or hold Personalis, Inc.?

Who are in the management team of Personalis, Inc.?

As of March 2022, the management team of Personalis, Inc. includes Jonathan MacQuitty (Independent Chairman), John West (CEO), and several Independent Directors: Patrick Balthrop, A. Blaine Bowman, Alan Colowick, Karin Eastham, and Kenneth Ludlum. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Personalis, Inc. includes the following individuals:<BR><BR>- Mr. Jonathan MacQuitty, Independent Chairman of the Board<BR>- Mr. John West, President, Chief Executive Officer, and Director<BR>- Mr. Patrick Balthrop, Independent Director<BR>- Mr. A. Blaine Bowman, Independent Director<BR>- Dr. Alan Colowick, Independent Director<BR>- Ms. Karin Eastham, Independent Director<BR>- Mr. Kenneth Ludlum, Independent Director<BR><BR>This team is responsible for guiding the company’s strategic direction and operations.

Is Personalis, Inc. technically bullish or bearish?

As of September 11, 2025, Personalis, Inc. shows a bullish technical trend overall, despite mixed short-term signals and underperformance compared to the S&P 500.

As of 11 September 2025, the technical trend for Personalis, Inc. has changed from mildly bullish to bullish. The weekly MACD is mildly bearish, but the monthly MACD is bullish, indicating a mixed short-term outlook. The weekly RSI is bullish, while the monthly RSI shows no signal. Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages are bullish, supporting the overall bullish stance. However, Dow Theory indicates a mildly bearish trend on the monthly chart and no trend on the weekly chart. <BR><BR>In terms of performance, Personalis has underperformed the S&P 500 over the past week and year, with a 1-week return of -4.59% compared to the S&P 500's 1.05%, and a 1-year return of 5.43% versus the S&P 500's 17.14%. Overall, the current technical stance is bullish, but with some caution due to mixed signals in shorter time frames.